Gene
PDGFB
PDGFB is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (57), Actionable biomarkers (1), Trial mentions (223), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention PDGFB. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 2 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 9 of 8,738 | 0.10% | not measured | |
| 2025 | 12 of 8,875 | 0.14% | not measured | |
| 2024 | 13 of 8,597 | 0.15% | not measured | |
| 2023 | 10 of 8,275 | 0.12% | 7 of 11,460 | 0.06% |
| 2022 | 14 of 8,285 | 0.17% | 17 of 13,598 | 0.13% |
| 2021 | 16 of 8,692 | 0.18% | 14 of 15,045 | 0.09% |
| 2020 | 8 of 7,640 | 0.10% | 21 of 14,459 | 0.15% |
| 2019 | 18 of 7,300 | 0.25% | 10 of 12,159 | 0.08% |
| 2018 | 12 of 6,927 | 0.17% | 14 of 11,854 | 0.12% |
| 2017 | 11 of 6,558 | 0.17% | 15 of 11,595 | 0.13% |
Showing 10 of 37 years.
Assay-provider ledger (57)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| SOMALogic, Inc | Reagent supplier | Clinical validation | 1 | March 28, 2026 |
| Olink Proteomics AB, Uppsala, Sweden | Reagent supplier | Clinical validation | 1 | December 12, 2025 |
| BioLegend, USA | Reagent supplier | Clinical validation | 1 | October 03, 2025 |
| BIO-RAD | Reagent supplier | Clinical validation | 3 | September 26, 2025 |
| Invitrogen by ThermoFisher Scientific | Reagent supplier | Clinical validation | 1 | September 26, 2025 |
Showing 5 of 57 assay-provider companies.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| PDGFB-COL1A1 fusion | Imatinib | response-associated | No disease recorded | Cancer Genome Interpreter |
Trial mentions (223)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT00926068 | Trial eligibility (AACT) |
| NCT05370196 | Trial eligibility (AACT) |
| NCT01600989 | Trial eligibility (AACT) |
| NCT01645891 | Trial eligibility (AACT) |
| NCT02049840 | Trial eligibility (AACT) |
Showing 5 of 223 trial mentions.
Target-disease associations (256)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 3-phosphoinositide-dependent protein kinase 1 measurement | measurement | GWAS credible sets |
| Alport syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
| B-cell acute lymphoblastic leukemia | cancer or benign tumor | Cancer Gene Census |
| Bardet-Biedl syndrome 16 | genetic, familial or congenital disease | Mouse knockout (IMPC) |
Showing 5 of 256 associations.
Vendor sourcing (665)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| AOTI Ltd. | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : * • Known allergy to any of the protocol-stipulated treatments, or non-tolerance of multilayer, multicomponent compression therapy * Acute thrombophleb... | View trial NCT06754735 |
| AOTI Ltd. | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : * Evidence of gangrene on any part of affected limb * Documented evidence of osteomyelitis on any part of affected limb * Index ulcer has exposed bone * I... | View trial NCT02326337 |
| AOTI Ltd. | Trial sponsor | Mentioned in trial textTrial free-text mention | Becaplermin | View trial NCT06754735 |
| AOTI Ltd. | Trial sponsor | Mentioned in trial textTrial free-text mention | Becaplermin | View trial NCT02326337 |
| AbbVie Inc. | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : * Participant has screening pelvic ultrasound or saline infusion sonohysterography (SIS) or magnetic resonance imaging (MRI; if SIS is unevaluable), resul... | View trial NCT03886220 |
Showing 5 of 665 sourcing records.
Trial-cited literature (258)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Hyaluronic acid: A novel approach in regenerative/reconstructive periodontal therapy? | Periodontology 2000 | 2025 | 15 |
| Effects of acetazolamide combined with remote ischemic preconditioning on risk of acute mountain sickness: a randomized clinical trial. | BMC medicine | 2024 | 16 |
| Good practice recommendations on add-ons in reproductive medicine†. | Human reproduction (Oxford, England) | 2023 | 123 |
| The emerging importance of lymphatics in health and disease: an NIH workshop report. | The Journal of clinical investigation | 2023 | 36 |
| Hypoxia Changes Energy Metabolism and Growth Rate in Non-Small Cell Lung Cancer Cells. | Cancers | 2023 | 25 |
Showing 5 of 258 papers.
Protein variant mentions (7)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.L239P | 1 | 2015 | PMID 25741868 |
| p.L286V | 2 | 2018 to 2021 | PMID 33911285, PMID 30046111 |
| p.M146L | 2 | 2018 to 2021 | PMID 33911285, PMID 30046111 |
| p.M1V | 1 | 2015 | PMID 25741868 |
| p.P24H | 1 | 2015 | PMID 25741868 |
Showing 5 of 7 variants.
Literature-extracted relations (30)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| HYALURONIC ACID | Chemical | associate |
Hyaluronic acid: A novel approach in regenerative/reconstructive periodontal therapy? | 2025 |
| Imatinib | Chemical | negative_correlate |
A Multicenter Phase II Study of Pazopanib in Patients with Unresectable Dermatofibrosarcoma Protuberans. | 2021 |
| CHOLECALCIFEROL | Chemical | negative_correlate |
Immune responses in the treatment of drug-sensitive pulmonary tuberculosis with phenylbutyrate and vitamin D<sub>3</sub> as host directed therapy. | 2018 |
| Sorafenib | Chemical | negative_correlate |
Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma. | 2012 |
| Imatinib | Chemical | negative_correlate |
Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate. | 2005 |
Showing 5 of 30 relation assertions.
Organizations publishing (244)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 10 | 2011 to 2023 |
| Harvard Medical School | Academic | 10 | 1996 to 2023 |
| Mass General Brigham | Hospital | 9 | 1996 to 2023 |
| Duke University Health System | Academic | 7 | 2010 to 2022 |
| Karolinska Institutet | Academic | 5 | 2005 to 2019 |
Showing 5 of 244 organizations.
Where PDGFB appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- measurement
- nervous system disease
- nutritional or metabolic disease
- phenotype
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
226 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.